Clinical Trial to Demonstrate the Effectiveness of Fecal Microbiota Transplantation for Selective Intestinal Decolonization of Patients Colonized by Carbapenemase-producing Klebsiella Pneumoniae
-
- STATUS
- Recruiting
-
- End date
- Sep 1, 2024
-
- participants needed
- 120
-
- sponsor
- Maimónides Biomedical Research Institute of Córdoba
Summary
Infections caused by carbapenemase-producing Enterobacteriaceae are frequent and often associated with high rates of mortality. Colonized patients are at increased risk of infection for these microorganisms. Moreover, they can act as a reservoir facilitating the transmission to other patients. To date, decolonization strategies with antibiotics have not obtained convincing results. For that reason our main objective is to investigate the efficacy of fecal microbiota transplantation (FMT) for selective intestinal decolonization of patients colonized by KPC-producing Klebsiella pneumoniae (Kp-KPC) at 30 days after FMT. Our hypothesis is that FMT is effective and safe for selective intestinal decolonization in patients colonized by Kp-KPC. The design of the study is a randomized, superiority, double blind controlled with placebo clinical trial.
The main variable is the percentage of patients with intestinal decolonization at 30 days after FMT in intention to treat population (all randomized patients). Decolonization will be considered as the abscence of isolation of Kp-KPC in culture from rectal swab together with the abscence of detection of carbapenemase by mean of polymerase chain reaction.
Secondary objectives are:
- To evaluate the safety of FMT.
- To determine if FMT is associated with decrease in the amount of bacteria at 7 days after FMT and 30 days after FMT.
- To evaluate if FMT is associated with persistent intestinal decolonization at 3 months after intervention.
- To study if FMT is associated with decrease in the incidence of Kp-KPC infections at 3 months after intervention.
- To evaluate if FMT is associated with decrease in mortality due to Kp-KPC infections at 3 months after intervention.
Details
| Condition | Carbapenemase-producing Enterobacteriaceae Infection |
|---|---|
| Treatment | Placebo, Fecal Microbiota Transplantation |
| Clinical Study Identifier | NCT04760665 |
| Sponsor | Maimónides Biomedical Research Institute of Córdoba |
| Last Modified on | 18 October 2021 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer